| Year |
Citation |
Score |
| 2022 |
Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, ... ... Macek TA, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nature Medicine. PMID 35715567 DOI: 10.1038/s41591-022-01867-3 |
0.29 |
|
| 2022 |
Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, ... ... Macek TA, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nature Medicine. PMID 35715566 DOI: 10.1038/s41591-022-01866-4 |
0.289 |
|
| 2021 |
Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, Iannaccone ST, Kuntz NL, Peña LDM, Shieh PB, Smith EC, Kwon JM, Zaidman CM, Schultz M, Feltner DE, ... ... Macek TA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. The Lancet. Neurology. 20: 284-293. PMID 33743238 DOI: 10.1016/S1474-4422(21)00001-6 |
0.269 |
|
| 2020 |
Macek TA, Suzuki K, Asin K, Kimura H. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor. The International Journal of Neuropsychopharmacology. PMID 32598478 DOI: 10.1093/Ijnp/Pyaa042 |
0.397 |
|
| 2019 |
Yurgelun-Todd DA, Renshaw PF, Goldsmith P, Uz T, Macek TA. A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects. Psychopharmacology. PMID 31773211 DOI: 10.1007/S00213-019-05366-1 |
0.438 |
|
| 2019 |
Day JW, Chiriboga CA, Crawford TO, Darras BT, Finkel RS, Connolly AM, Iannaccone ST, Kuntz NL, Pena LD, Schultz M, Shieh PB, Smith EC, Farrar M, Feltner DE, Ogrinc FG, ... Macek TA, et al. 066 Avxs-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): pivotal phase 3 study (STR1VE) update Journal of Neurology, Neurosurgery & Psychiatry. 90: A22.1-A22. DOI: 10.1136/Jnnp-2019-Anzan.58 |
0.394 |
|
| 2019 |
Day JW, Chiriboga CA, Crawford TO, Darras BT, Finkel RS, Connolly AM, Iannaccone ST, Kuntz NL, Peña LD, Schultz M, Shieh PB, Smith EC, Kausar I, Feltner DE, Ogrinc FG, ... ... Macek TA, et al. 250 AVXS-101 phase 3 study in spinal muscular atrophy type 1 Journal of Neurology, Neurosurgery, and Psychiatry. 90. DOI: 10.1136/Jnnp-2019-Abn-2.202 |
0.373 |
|
| 2018 |
Szabo S, Merikle E, Lozano-Ortega G, Powell L, Macek T, Cline S. Assessing the Relationship between Performance on the University of California Performance Skills Assessment (UPSA) and Outcomes in Schizophrenia: A Systematic Review and Evidence Synthesis. Schizophrenia Research and Treatment. 2018: 9075174. PMID 30687553 DOI: 10.1155/2018/9075174 |
0.347 |
|
| 2018 |
Macek TA, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J, Mahableshwarkar AR. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophrenia Research. PMID 30190165 DOI: 10.1016/J.Schres.2018.08.028 |
0.446 |
|
| 2017 |
Goldsmith P, Affinito J, McCue M, Tsai M, Roepcke S, Xie J, Gertsik L, Macek TA. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events. Drugs in R&D. PMID 29103081 DOI: 10.1007/S40268-017-0214-8 |
0.416 |
|
| 2017 |
Mahableshwarkar AR, Calabrese JR, Macek TA, Budur K, Adefuye A, Dong X, Hanson E, Sachs GS. Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial. Journal of Affective Disorders. 221: 275-282. PMID 28662460 DOI: 10.1016/J.Jad.2017.06.044 |
0.435 |
|
| 2017 |
Mahableshwarkar AR, McCue M, Dong X, Hanson E, Affinito J, Macek TA. Subset analyses by race of a phase 2 study of TAK-063 in subjects with acute exacerbations of psychotic symptoms European Neuropsychopharmacology. 27. DOI: 10.1016/S0924-977X(17)31681-4 |
0.356 |
|
| 2016 |
Tsai M, Chrones L, Xie J, Gevorkyan H, Macek TA. A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. Psychopharmacology. PMID 27572830 DOI: 10.1007/S00213-016-4412-9 |
0.422 |
|
| 2016 |
Takano A, Stenkrona P, Stepanov V, Amini N, Martinsson S, Tsai M, Goldsmith P, Xie J, Wu J, Uz T, Halldin C, Macek TA. A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor. Neuroimage. PMID 27423256 DOI: 10.1016/J.Neuroimage.2016.06.047 |
0.384 |
|
| 2016 |
Wickwire EM, Williams SG, Roth T, Capaldi VF, Jaffe M, Moline M, Motamedi GK, Morgan GW, Mysliwiec V, Germain A, Pazdan RM, Ferziger R, Balkin TJ, MacDonald ME, Macek TA, et al. Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 27002812 DOI: 10.1007/S13311-016-0429-3 |
0.312 |
|
| 2015 |
Takano A, Stenkrona P, Stepanov V, Amini N, Martinsson S, Tsai M, Goldsmith P, Wu J, Xie J, Uz T, Macek T, Halldin C. P.1.i.028 Brain phosphodiesterase 10A occupancy measured by PET after oral administration of TAK-063, a newly developed phosphodiesterase 10A inhibitor, in human volunteers European Neuropsychopharmacology. 25: S316. DOI: 10.1016/S0924-977X(15)30387-4 |
0.362 |
|
| 2015 |
Takano A, Stepanov V, Stenkrona P, Amini N, Martinsson S, Tsai M, Goldsmith P, Wu J, Xie J, Uz T, Macek T, Halldin C. P.1.i.027 Quantitative analysis and test-retest reproducibility of a new phosphodiesterase 10A PET radioligand [11C]T-773 in human brain European Neuropsychopharmacology. 25: S315. DOI: 10.1016/S0924-977X(15)30386-2 |
0.34 |
|
| 2013 |
Sorensen SD, Macek TA, Cai Z, Saugstad JA, Conn PJ. Dissociation of protein kinase-mediated regulation of metabotropic glutamate receptor 7 (mGluR7) interactions with calmodulin and regulation of mGluR7 function (Molecular Pharmacology (2002) 61 (1303-1312)) Molecular Pharmacology. 84. DOI: 10.1124/Mol.113.12Er13 |
0.38 |
|
| 2010 |
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. Journal of Affective Disorders. 126: 358-65. PMID 20537396 DOI: 10.1016/J.Jad.2010.04.005 |
0.463 |
|
| 2010 |
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders. 122: 27-38. PMID 20096936 DOI: 10.1016/J.Jad.2009.12.028 |
0.352 |
|
| 2010 |
McIntyre R, Cohen M, Zhao J, Alphs L, Macek T, Szegedi A, Panagides J. P01-69 - Long-term asenapine treatment for bipolar disorder: a double-blind 40-week extension study European Psychiatry. 25: 290. DOI: 10.1016/S0924-9338(10)70288-1 |
0.465 |
|
| 2009 |
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders. 11: 673-86. PMID 19839993 DOI: 10.1111/J.1399-5618.2009.00748.X |
0.418 |
|
| 2009 |
McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disorders. 11: 815-26. PMID 19832806 DOI: 10.1111/J.1399-5618.2009.00749.X |
0.424 |
|
| 2008 |
McIntyre R, Alphs L, Cohen M, Keller DS, Macek T, Panagides J. 37 – Long-term double-blind extension studies of asenapine vs. olanzapine in patients with bipolar mania Schizophrenia Research. 98: 48-49. DOI: 10.1016/J.Schres.2007.12.104 |
0.383 |
|
| 2008 |
McIntyre R, Hirschfeld R, Alphs L, Cohen M, Macek T, Panagides J. Randomized and placebo-controlled studies of asenapine in the treatment of acute mania in bipolar I disorder Schizophrenia Research. 98: 5-6. DOI: 10.1016/J.Schres.2007.12.006 |
0.409 |
|
| 2008 |
McIntyre R, Hirschfeld R, Alphs L, Cohen M, Macek T, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: Outcomes from two randomized and placebo-controlled trials Journal of Affective Disorders. 107. DOI: 10.1016/J.Jad.2007.12.016 |
0.394 |
|
| 2007 |
McIntyre R, Panagides J, Alphs L, Cohen M, Lancaster S, Macek T. P.2.e.012 Treatment of mania in bipolar I disorder: a placebo- and olanzapine-controlled trial of asenapine (ARES 7501005) European Neuropsychopharmacology. 17. DOI: 10.1016/S0924-977X(07)70567-9 |
0.402 |
|
| 2006 |
Nguyen V, Sweet BV, Macek T. Defining the phases of clinical trials. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 63: 710-1. PMID 16595808 DOI: 10.2146/ajhp050537 |
0.261 |
|
| 2004 |
Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 15: 1705-11. PMID 15520075 DOI: 10.1093/Annonc/Mdh438 |
0.368 |
|
| 2002 |
Sorensen SD, Macek TA, Cai Z, Saugstad JA, Conn PJ. Dissociation of protein kinase-mediated regulation of metabotropic glutamate receptor 7 (mGluR7) interactions with calmodulin and regulation of mGluR7 function. Molecular Pharmacology. 61: 1303-12. PMID 12021391 DOI: 10.1124/Mol.61.6.1303 |
0.392 |
|
| 2000 |
Schaffhauser H, Cai Z, Hubalek F, Macek TA, Pohl J, Murphy TJ, Conn PJ. cAMP-dependent protein kinase inhibits mGluR2 coupling to G-proteins by direct receptor phosphorylation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 5663-70. PMID 10908604 DOI: 10.1523/Jneurosci.20-15-05663.2000 |
0.42 |
|
| 1999 |
Macek TA, Schaffhauser H, Conn PJ. Activation of PKC disrupts presynaptic inhibition by group II and group III metabotropic glutamate receptors and uncouples the receptor from GTP-binding proteins. Annals of the New York Academy of Sciences. 868: 554-7. PMID 10414335 DOI: 10.1111/J.1749-6632.1999.Tb11327.X |
0.394 |
|
| 1998 |
Macek TA, Schaffhauser H, Conn PJ. Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 6138-46. PMID 9698308 DOI: 10.1523/Jneurosci.18-16-06138.1998 |
0.43 |
|
| 1996 |
Macek TA, Winder DG, Gereau RW, Ladd CO, Conn PJ. Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses. Journal of Neurophysiology. 76: 3798-806. PMID 8985877 DOI: 10.1152/Jn.1996.76.6.3798 |
0.605 |
|
| 1996 |
Conn P, Macek TA, Gereau RW. Physiological roles of multiple mGluR subtypes in rat hippocampus Neuropharmacology. 35: A9. DOI: 10.1016/0028-3908(96)84683-1 |
0.518 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2023 |
Finkel RS, Darras BT, Mendell JR, Day JW, Kuntz NL, Connolly AM, Zaidman C, Crawford TO, Butterfield RJ, Shieh PB, Tennekoon G, Brandsema JF, Iannaccone ST, Shoffner J, Kavanagh S, ... Macek TA, et al. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG). Journal of Neuromuscular Diseases. PMID 36911944 DOI: 10.3233/JND-221560 |
0.143 |
|
| 2024 |
Pandina GJ, Busner J, Kempf L, Fallon J, Alphs LD, Acosta MT, Berger AK, Day S, Dunn J, Villalta-Gil V, Grabb MC, Horrigan JP, Jacobson W, Kando JC, Macek TA, et al. Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group. Innovations in Clinical Neuroscience. 21: 52-60. PMID 38495603 |
0.066 |
|
| 2008 |
de Cárcer DA, Martín M, Mackova M, Macek T, Karlson U, Rivilla R. The introduction of genetically modified microorganisms designed for rhizoremediation induces changes on native bacteria in the rhizosphere but not in the surrounding soil. The Isme Journal. 1: 215-23. PMID 18043632 DOI: 10.1038/sj.ismej.2007.27 |
0.042 |
|
| 2005 |
Villacieros M, Whelan C, Mackova M, Molgaard J, Sánchez-Contreras M, Lloret J, Aguirre de Cárcer D, Oruezábal RI, Bolaños L, Macek T, Karlson U, Dowling DN, Martín M, Rivilla R. Polychlorinated biphenyl rhizoremediation by Pseudomonas fluorescens F113 derivatives, using a Sinorhizobium meliloti nod system to drive bph gene expression. Applied and Environmental Microbiology. 71: 2687-94. PMID 15870360 DOI: 10.1128/AEM.71.5.2687-2694.2005 |
0.03 |
|
| Hide low-probability matches. |